Franklin Lakes-based BD (Becton, Dickinson and Company), a leader in medical technology, announced on Wednesday the appointment of Shawn Bevec as senior vice president of investor relations, effective Jan. 20.
Bevec will lead the company’s communication strategy with the financial community, focusing on articulating BD’s long-term growth initiatives and shareholder value drivers. He will report to interim Chief Financial Officer Vitor Roque until a permanent CFO is named.
The appointment comes at a pivotal time for BD. Just this week, the company announced a $110 million investment in its Nebraska manufacturing facilities to support the booming GLP-1 and biologics drug delivery markets. Bevec is expected to be a key voice in explaining these strategic pivots to Wall Street.
“As BD enters an exciting new chapter of growth, Shawn will be instrumental in articulating our strategy, performance and growth opportunities,” Roque said. “His deep expertise in investor relations and equity research uniquely position him to lead this function as we aim to deliver greater value for patients and shareholders.”
Bevec joins BD from Quest Diagnostics, where he served as vice president of investor relations. His career is characterized by a rare blend of scientific foundation and financial acumen:
-
Financial experience: Previously served as a sell-side research analyst at Deutsche Bank and Susquehanna International Group, covering healthcare services and medical devices.
-
Scientific background: Held research and development roles at Pfizer and Johnson & Johnson early in his career.
-
Education: Holds a B.S. in Chemistry from the University of Arizona and an MBA from NYU’s Leonard N. Stern School of Business.
